Alemtuzumab
Campath, Lemtrada (alemtuzumab) is an antibody pharmaceutical. Alemtuzumab was first approved as Campath on 2001-05-07. It is used to treat b-cell chronic lymphocytic leukemia in the USA. It has been approved in Europe to treat multiple sclerosis. The pharmaceutical is active against CAMPATH-1 antigen.
| Trade Name | Lemtrada |
|---|---|
| Common Name | Alemtuzumab |
| Indication | b-cell chronic lymphocytic leukemia, multiple sclerosis |
| Drug Class | Monoclonal antibodies: humanized, tumors as target |
